Welcome to our dedicated page for UroGen Pharma Ltd. Ordinary Shares news (Ticker: $URGN), a resource for investors and traders seeking the latest updates and insights on UroGen Pharma Ltd. Ordinary Shares stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect UroGen Pharma Ltd. Ordinary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of UroGen Pharma Ltd. Ordinary Shares's position in the market.
UroGen Pharma (URGN) is set to participate in upcoming investor conferences like Citizens JMP Life Sciences Conference and H.C. Wainwright BioConnect Conference in May 2024. The company aims to present its innovative solutions for urothelial and specialty cancers, showcasing its commitment to developing and commercializing effective treatments.
UroGen Pharma has presented a real-world retrospective analysis at AUA 2024, reporting an 86% Recurrence-Free Survival (RFS) at 24 months with JELMYTO® for patients with low-grade Ta upper tract urothelial carcinoma who were complete responders to induction therapy. No differences in RFS were found based on treatment usage, tumor characteristics, or timing of administration. Patients who received maintenance therapy showed a 100% RFS at 24 months compared to 61% for those who did not receive maintenance therapy. These results suggest JELMYTO's potential in treating UTUC and improving long-term outcomes.
UroGen Pharma announced the results from the ATLAS trial, showing the durability of response in new and recurrent low-grade intermediate-risk non-muscle invasive bladder cancer patients treated with UGN-102. The data revealed high probabilities of remaining in complete response for both patient groups, indicating the potential of UGN-102 as a primary treatment option. The Phase 3 ATLAS study demonstrated favorable Disease Free Survival and Durability of Response rates with UGN-102 compared to the standard treatment. These findings highlight the promise of UGN-102 in transforming the landscape of LG-IR-NMIBC treatment, potentially reducing the need for repetitive surgeries and their associated risks and burdens.
UroGen Pharma highlights a real-world study on JELMYTO for low-grade upper tract urothelial cancer, showing a 60% complete response rate and lower stricture rate compared to the OLYMPUS pivotal trial. The study, presented at the American Urological Association Meeting 2024, demonstrates the safety and efficacy of retrograde administration of JELMYTO, with insights for positive outcomes. This sub-analysis involves 20 patients with promising results, indicating the potential of JELMYTO in the treatment of urothelial cancers.
UroGen Pharma, a biotech company focused on urothelial and specialty cancers, will release its 2024 first-quarter financial results on May 13, 2024. A conference call and webcast are scheduled for the same day at 10:00 AM ET.
